Evasc Overview
- Founded
- 2001

- Status
- Private
- Employees
- 24

- Latest Deal Type
- Series A
- Latest Deal Amount
- $7.42M

- Investors
- 1
Evasc General Information
Description
Developer of novel endovascular medical devices designed to treat cerebral aneurysms. The company's medical devices offer to effectively treat an aneurysm by bridging the neck, creating flow effect, and providing scaffolding to enable endothelial growth, enabling healthcare providers to undertake the endovascular repair of cerebral aneurysms, to provide a much better standard of care and rate of successful treatment outcomes than previously possible.
Contact Information
- 107-1099 West 8th Avenue
- Vancouver, British Columbia V6H 1C3
- Canada
Evasc Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Later Stage VC (Series A) | 14-Jun-2017 | $7.42M | 0000 | Completed | Generating Revenue | |
1. Seed Round | 000.00 | 000.00 | Completed | Startup |
Evasc Executive Team (5)
Evasc Board Members (5)
Name | Representing | Role | Since |
---|---|---|---|
Carl Simpson | Self | Board Member | 000 0000 |
Daguang Wang Ph.D | Self | Board Member | 000 0000 |
David Ostrow MD | Self | Board Member | 000 0000 |
Donald Ricci MD | Evasc | Co-Founder, President, Chief Executive Officer & Board Member | 000 0000 |
Evasc Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialEvasc Investors (1)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Yonghua Capital | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |